Status: Not yet recruiting
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
The purpose of this study is to evaluate the efficacy and safety of Letrozole SIE (injectable) compared to Femara® (oral tablet), both given together with ribociclib, for the first-line treatment of postmenopausal women with HR-positive, HER2-negative, inoperable locally advanced or metastatic breast cancer.
Participants needed: 300
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: Rovi Pharmaceuticals LaboratoriesUpdated: Apr 2, 2026
Eligibility criteria
Female participants with inoperable locally advanced or metastatic breast cancer... [+8]
Participants with advanced, symptomatic, visceral spread who are at risk of life... [+18]